Insider buying last 90 days
No open-market insider purchases were filed for VRTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VRTX insider filing, plotted on the chart in Gekko.Open VRTX in Gekko
NASDAQ: VRTX
Vertex Pharmaceuticals (VRTX) Stock Analysis & Forecast
Nov 4 close
$549.04+18.28 (+3.4%)
Gekko Brief
AI summaryNov 4 closeVertex Pharmaceuticals rose this week after third-quarter results showed revenue up 12% year-on-year to $3.44 billion, with the cystic fibrosis portfolio and newer products CASGEVY and PALSONIFY cited as drivers, and full-year 2026 sales guidance raised. Adjusted earnings per share missed expectations amid higher operating expenses, R&D investment, and costs tied to the Crinetics Pharmaceuticals acquisition, and shares fell 3.61% on 3 November following the print before rebounding. Company leaders voiced confidence ahead of the FDA decision on povetacicept, and BMO Capital raised its price target to $620 from $600 while maintaining an Outperform rating; other analysts also lifted targets following the results.
VRTX closed at $549.04, up 3.4%, sitting above both its 50-day average of $522.91 and 200-day average of $480.77, with one-month and three-month returns of 9.3% and 13.4%. The GekkoIndex reading of 52.3 places the stock in the Neutral zone, down 2.1 over five sessions, while the price sits 16.8% above the Gekko Fair Value of $470.24.
The next earnings date is 11 February 2027, 98 days out, beyond a typical 20-trading-day hold. Over the last 90 days, Congress recorded 1 buy and 0 sales. Seasonality over the next 20 trading days has averaged a 1.5% return across 5 years, rising in 3 of them. The pending FDA decision on povetacicept is worth noting given its link to recent analyst commentary.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Vertex Pharmaceuticals price vs fair value
Close $549.04200-day averageGekko Fair Value $470.24
Vertex Pharmaceuticals quick facts
- Market cap
- $139.2B
- P/E ratio
- 32.2
- Forward P/E
- 26.4
- EPS, TTM
- $17.17
- Revenue, TTM
- $12.59B
- Profit margin
- 35%
- Dividend yield
- —
- Beta
- 0.28
- Volume
- 1.81M avg 1.60M
- 1-year return
- +28.9%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±4.4%
- 50-day average
- $522.91
- 200-day average
- $480.77
- Next earnings
- Feb 11 after close
- Shares outstanding
- 253.5M
Vertex Pharmaceuticals swing-trade checklist
Vertex Pharmaceuticals scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $549.04 is above the 50-day ($522.91) and 200-day ($480.77) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52.3, Neutral
Reading 52.3 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
16.8% above
Price is 16.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 98 days
Next report Feb 11, 2027, 98 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.5% on average
From this point in the calendar, the next 20 trading days averaged +1.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Vertex Pharmaceuticals stock chart and price history
Vertex Pharmaceuticals closed at $549.04 on Nov 4, 2026, +28.9% over the past year, inside a 52-week range of $403.16 to $568.67.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +9.3%
- 3 months
- +13.4%
- 6 months
- +28.4%
- 1 year
- +28.9%
The full VRTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VRTX in Gekko
Follow Vertex Pharmaceuticals through every session
Put VRTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VRTX in GekkoFree for 7 days. No credit card required.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals makes medicines aimed at cystic fibrosis, a disease tied to mutations in the CFTR gene. Its lineup of cleared drugs, among them SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO and TRIKAFTA, is built around correcting the effects of particular gene defects, and TRIKAFTA is meant for CF patients six years old or older who carry the F508del mutation on at least one allele. This CF-focused portfolio is the foundation the company has built its name on.
Past its established CF business, Vertex runs a wide set of experimental programs at different clinical stages, touching on alpha-1 antitrypsin deficiency, a kidney disorder called APOL1-mediated FSGS, Type 1 diabetes, several categories of pain, and severe sickle cell disease together with transfusion-dependent beta-thalassemia. In the US its drugs move to patients via specialty pharmacies and distribution partners, while sales abroad run through distributors, retail pharmacy chains, hospitals and clinics. The company also pairs with outside research partners, including CRISPR Therapeutics, Moderna, Kymera Therapeutics and Merck KGaA, among others.
Vertex traces back to 1989 and operates out of Boston, Massachusetts. Its stock is listed on the NASDAQ under the ticker VRTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- vrtx.com
Vertex Pharmaceuticals GekkoIndex: the smart money zone
Vertex Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.3, in the Neutral zone, down 2.1 points over five sessions.
52.3Neutral
Down 2.1 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 21 | +1.4% | +5.7% | ||
| Accumulation | 233 | +0.6% | +1.6% | ||
| Neutral (current zone) | 415 | 0.0% | +0.1% | ||
| Distribution | 27 | −0.9% | +0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average VRTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the VRTX price, zone by zone.Track VRTX in Gekko
Is Vertex Pharmaceuticals stock overvalued? Gekko Fair Value
Vertex Pharmaceuticals trades 16.8% above Gekko Fair Value of $470.24, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Vertex Pharmaceuticals shares are worth, recalculated every trading day.
$470.24
Gekko Fair Value, Nov 4, 2026
16.8% Overvalued
At the end of Aug 2026 the price was 14.3% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VRTX in Gekko
Vertex Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Vertex Pharmaceuticals, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Vertex Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $473.8M
- As a share of market cap
- 0.34%
- Trailing four quarters
- $2.24B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds VRTX.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Vertex Pharmaceuticals earnings: next date and track record
Vertex Pharmaceuticals reports on Feb 11, 2027, after the close (98 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Feb 11, 2027
Expected after the close, 98 days away
- EPS estimate
- $4.38
- Revenue estimate
- $3.50B
5 of 8reports beat the EPS estimate
±5.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- Vertex reported Q2 2026 total revenue growth of 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. Key pipeline milestones include BLA acceptance for Pove in IgAN with a November 30 PDUFA date, expanded CASGEVY labeling for ages 2-11, and cleared IND for VX-017 in Type 1 diabetes. Vertex announced acquisition of Crinetics Pharmaceuticals to establish a fifth pillar in rare endocrine diseases.
- Guidance
- Vertex expects to complete AMPLITUDE Phase III enrollment by year-end 2026 and report interim analysis results in early 2027. Proof-of-concept study results in DM1 and initial VX-828 patient data expected in second half of 2026. Crinetics acquisition expected to accelerate revenue growth and enhance long-term earnings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $4.20 est $4.15 | $3.33B est $3.23B | +0.3% |
| May 4, 2026 | $4.47 est $4.31 | $2.99B est $2.99B | +0.1% |
| Feb 12, 2026 | $5.03 est $5.15 | $3.19B est $3.18B | +6.6% |
| Nov 3, 2025 | $4.80 est $4.58 | $3.08B est $3.06B | −0.9% |
| Aug 4, 2025 | $4.52 est $4.29 | $2.96B est $2.91B | −18.9% |
| May 5, 2025 | $4.06 est $4.25 | $2.77B est $2.86B | −10.2% |
| Feb 10, 2025 | $3.98 est $4.02 | $2.91B est $2.78B | −3.0% |
| Nov 4, 2024 | $4.38 est $4.13 | $2.77B est $2.69B | +6.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Vertex Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Vertex Pharmaceuticals is $571.46, +4.1% from the last close, from 21 firms rating the stock in the last 90 days.
$571.46consensus 12-month target, +4.1% from the last close
Now $549.04Avg $571.46
Low $442High $725
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | H.C. Wainwright | $641 | +16.7% |
| Nov 4 | Barclays | $626 | +14.0% |
| Nov 4 | UBS | $640 | +16.6% |
| Nov 3 | Citi | $585 | +6.5% |
| Nov 3 | Goldman Sachs | $725 | +32.0% |
+0.1%average 20-day move after past Neutral readings
+1.5%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Vertex Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Vertex Pharmaceuticals averaged +1.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.2% | 2 of 5 |
| Next 10 trading days | −1.5% | 2 of 5 |
| Next 15 trading days | −2.1% | 2 of 5 |
| Next 20 trading days | +1.5% | 3 of 5 |
| Next 30 trading days | +3.7% | 3 of 5 |
For scale, VRTX’s typical 20-trading-day move in either direction is about 4.4%.
Vertex Pharmaceuticals market cap and key statistics
Vertex Pharmaceuticals’s market cap is $139.2B, with a P/E ratio of 32.2 and revenue of $12.59B over the last twelve months.
Valuation
- Market cap
- $139.2B
- P/E ratio
- 32.2
- Forward P/E
- 26.4
- EPS, TTM
- $17.17
- Gekko Fair Value
- $470.24
Trading
- Volume
- 1.81M
- Avg volume, 20 days
- 1.60M
- 52-week high
- $568.67
- 52-week low
- $403.16
- Shares outstanding
- 253.5M
Financials
- Revenue, TTM
- $12.59B
- Profit margin
- 35%
- Return on equity
- 23.5%
- Quarterly earnings growth, YoY
- +8.0%
Risk and income
- Beta
- 0.28
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±4.4%
Vertex Pharmaceuticals stock news this week
Coverage of Vertex Pharmaceuticals this week reads positive: 10 positive, 5 neutral and 2 negative headlines.
- Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by AIA Group LtdDefense World, Nov 4
- Vertex Pharmaceuticals Thrives on Higher Sales and GuidanceFXEmpire, Nov 4
- Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTXDefense World, Nov 4
- Vertex Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $592.56, Implies 7% UpsideTradingView, Nov 3
- Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.61% on Nov 3: Drivers Behind the MovementTradingKey, Nov 3
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugBioPharma Dive, Nov 3
Vertex Pharmaceuticals peers
Vertex Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Vertex Pharmaceuticals stock FAQ
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $139.2B at the Nov 4, 2026 close of $549.04, with 253.5M shares outstanding. The shares trade on a P/E ratio of 32.2.
What is the Vertex Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Vertex Pharmaceuticals is $571.46, +4.1% from the last close. Of the 21 firms that rated the stock in the last 90 days, 19 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Vertex Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Vertex Pharmaceuticals is overvalued: the Nov 4, 2026 close of $549.04 is 16.8% above Gekko Fair Value of $470.24. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Vertex Pharmaceuticals report earnings next?
Vertex Pharmaceuticals is expected to report on Feb 11, 2027, after the market closes (98 days away). Analysts expect earnings of $4.38 per share on revenue of $3.50B. Vertex Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 5.8% on average across the report.
What is Vertex Pharmaceuticals’s 52-week high and low?
Vertex Pharmaceuticals’s 52-week high is $568.67 and its 52-week low is $403.16; it closed at $549.04 on Nov 4, 2026, +28.9% over the past year.
Is Vertex Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Vertex Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.